Juan Manuel Garcia‐Illarramendi

Juan Manuel Garcia‐Illarramendi

Auto-generated profile, based on publicly available information

Juan Manuel Garcia‐Illarramendi

Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
VJValentin Junet
Valentin Junet
PMPedro Matos‐Filipe
Pedro Matos‐Filipe
JGJuan Manuel García‐Illarramendi
Juan Manuel García‐Illarramendi
EREsther Ramírez
Esther Ramírez
BOBaldo Oliva
Baldo Oliva
RMRafael Morales
Rafael Morales
Oncology treatments require continuous individual adjustment based on the measurement of multiple clinical parameters. Prediction tools exploiting the patterns present in the clinical data could be used to assist decision making and ease the burden associated to the interpretation of all these parameters. The goal of this study was to predict the evolution of patients with pancreatic cancer at their next visit using information routinely recorded in health records, providing a decision‐support system for clinicians. We selected hematological variables as the visit's clinical outcomes, under the assumption that they can be predictive of the evolution of the patient. Multivariate models based on regression trees were generated to predict next‐visit values for each of the clinical outcomes selected, based on the longitudinal clinical data as well as on molecular data sets streaming from in silico simulations of individual patient status at each visit. The models predict, with a mean prediction score (balanced accuracy) of 0.79, the evolution trends of eosinophils, leukocytes, monocytes, and platelets. Time span between visits and neutropenia were among the most common factors contributing to the predicted evolution. The inclusion of molecular variables from the systems‐biology in silico simulations provided a molecular background for the observed variations in the selected outcome variables, mostly in relation to the regulation of hematopoiesis. In spite of its limitations, this study serves as a proof of concept for the application of next‐visit prediction tools in real‐world settings, even when available data sets are small.

1 July 2026 in Nature Communications
Verified
Journal Article
Open access
KFKaori L. Fonseca
Kaori L. Fonseca
JFJudith Farrés
Judith Farrés
KBKetevan Barbakadze
Ketevan Barbakadze
IJIza Jikia
Iza Jikia
MTMalkhaz Tsotskhalashvili
Malkhaz Tsotskhalashvili
CVCris Vilaplana
Cris Vilaplana
Drug-resistant tuberculosis remains a major global health challenge, and excessive inflammation may contribute to tissue damage and poor outcomes. We conducted a phase IIA prospective open-label pilot trial (ClinicalTrials.gov: NCT02781909) evaluating adjunctive ibuprofen in adults with pulmonary pre-extensively drug-resistant (pre-XDR) or extensively drug-resistant (XDR) tuberculosis in Georgia. Twenty-eight participants received individualized background anti-tuberculosis regimens alone ( n = 14) or with ibuprofen 400 mg daily for 2 months ( n = 14) and were followed for 6 months. The primary efficacy outcome was the proportion of participants showing clinical and/or microbiological benefit, assessed by sputum culture conversion, radiological evolution, and WHO-defined treatment outcomes. Secondary outcomes were safety and tolerability, health-related quality of life, and inflammatory and transcriptomic responses. Adding adjunctive ibuprofen did not improve month-2 sputum culture negativity, time to stable culture conversion, radiological evolution, or final treatment outcomes. Safety and tolerability were similar between groups. Adverse events were recorded and reviewed, but not formally graded for severity. Ibuprofen treatment was associated with numerically greater reductions in several blood-based inflammatory measures and in transcriptomic signature scores associated with poor tuberculosis outcomes. These findings are exploratory and do not demonstrate clinical benefit but indicate biological activity and support evaluation of anti-inflammatory host-directed therapies in larger controlled trials.

29 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KFKaori L. Fonseca
Kaori L. Fonseca
JFJudith Farrés
Judith Farrés
KBKetevan Barbakadze
Ketevan Barbakadze
IJIza Jikia
Iza Jikia
MTMalkhaz Tsotskhalashvili
Malkhaz Tsotskhalashvili
CVCris Vilaplana
Cris Vilaplana
Background: Drug-resistant tuberculosis (TB) remains a formidable global health challenge. Host-directed therapies (HDTs) offer the potential to mitigate tissue damage, reduce treatment duration, and improve clinical outcomes by modulating immune responses. We assessed the safety and potential efficacy of adjunctive ibuprofen—an inexpensive, well-tolerated non-steroidal anti-inflammatory drug—in patients with pre-extensively drug-resistant (pre-XDR) and extensively drug-resistant (XDR) TB. Methods: In this prospective, open-label, randomized pilot study ( NCT02781909 ) conducted in Georgia, 28 adults with bacteriologically confirmed pulmonary pre-XDR or XDR-TB were randomized 1:1 to receive either standard-of-care (SoC) TB treatment alone (n=14) or SoC plus 400 mg ibuprofen daily during the first 2 months (n=14). Participants were followed for 6 months. The primary endpoints were early sputum culture conversion and radiological improvement. Secondary endpoints included WHO-defined final treatment outcomes, safety, health-related quality of life (HQoL), and changes in inflammatory markers. Findings: By week 2, culture negativity was achieved in 27% of control participants versus 9% in the ibuprofen group (risk difference 18%, 95% CI −13 to 50). The median time to culture conversion was 4 months in both groups. At month 2, favourable X-ray evolution was observed in 64% of controls compared with 54% of the ibuprofen group (risk difference 9%, 95% CI −32 to 50), with 90% of participants in each group showing improvement by month 6. Final treatment outcomes were comparable (≈71% cured) and the incidence of safety-related events did not differ significantly. Notably, the ibuprofen group exhibited greater proportional reductions in inflammatory markers—including a statistically significant decrease in the monocyte-to-lymphocyte ratio at months 2 and 5, along with reductions in interferon gamma levels and the enrichment score for Thompson_FAIL_13 gene signature at month 6. Interpretation: Although adjunctive ibuprofen did not improve primary microbiological or radiological endpoints, its excellent safety profile and significant anti-inflammatory effects support its potential role as an immune-modulating adjunct in the treatment of drug-resistant TB. These findings warrant further investigation in larger studies to optimize dosing and evaluate clinical benefits. Funding: Catalan Government (2021 SGR 00920), Spanish Government-FEDER Funds (CPII18/00031, PI20/01424 and CB06/06/0031, and European Union’s Horizon 2020 research and innovation program under grant agreement No. 847762 (SMA-TB project). Research in context: Evidence before this study: Drug-resistant tuberculosis (TB) remains a major global health challenge. Host-directed therapies (HDTs) have emerged as a means to shorten treatment, improve outcomes and limit tissue damage from excessive inflammation. In preclinical models of active TB, non-steroidal anti-inflammatory drugs (NSAIDs) enhanced bacterial control and reduced lung pathology. Clinical data on NSAIDs as HDTs are scarce, confined to small studies in tuberculous meningitis and TB patients with diabetes, which reported encouraging but preliminary benefits. Added value of this study: This is the first randomized trial of adjunctive ibuprofen in patients with pre-XDR and XDR-TB. Whilst ibuprofen did not confer microbiological or clinical benefit at two and six months, it was safe, well tolerated and significantly lowered systemic inflammatory markers. Baseline imbalances in disease severity and high inter-patient variability likely obscured any clinical effect despite reduced inflammation. Implications of all the available evidence: Our findings demonstrate that ibuprofen is a safe adjunct in drug-resistant TB and can mitigate harmful inflammation. Future work should explore optimised dosing regimens, alternative HDT candidates and more sensitive or tailored endpoints—potentially focusing on patient subgroups most likely to benefit. Such refinements will be essential to reveal the true clinical value of HDTs across diverse TB populations.

13 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
PMPedro Matos-Filipe
Pedro Matos-Filipe
JGJuan Manuel García-Illarramendi
Juan Manuel García-Illarramendi
GJGuillem Jorba
Guillem Jorba
BOBaldo Oliva
Baldo Oliva
JFJudith Farrés
Judith Farrés
JMJosé Manuel Mas
José Manuel Mas
Introduction Randomized clinical trials (RCT) are limited in reflecting observable results out of controlled settings, which requires the execution of further lengthy observational studies. The usage of real-world data (RWD) has been recently considered to be a viable alternative to overcome these issues and complement certain clinical conclusions. Transcriptomics and other high-throughput data contain a molecular description of medical conditions and disease states. When linked to RWD, including demographical information, transcriptomics data is capable of elucidating nuances in disease pathways in specific patient populations. This work focuses on the construction of a patient repository database with clinical information resulting from the integration of publicly available transcriptomics datasets. Results Samples from patient data were integrated into the patient repository by using a new post-processing technique allowing for the combined usage of samples originating from Gene Expression Omnibus (GEO) datasets. RWD was mined from GEO samples’ metadata, and a clinical and demographical characterization of the database was obtained. Our post-processing technique, that we’ve called MACAROON, aims to uniformize, and integrate transcriptomics data (considering batch effects and possible processing-originated artefacts). This process was able to better reproduce the down streaming biological conclusions in a 10% enhancement (compared to other methods available). RWD mining was done through a manually curated synonym dictionary allowing for the correct assignment (95.33% median accuracy) of medical conditions. Conclusion Our strategy produced a RWD repository, including molecular information and clinical and demographical RWD. The exploration of these data facilitates shedding light on clinical outcomes and pathways specific to predetermined populations of patients by integrating multiple public datasets.

13 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JGJuan M. Garcia-Illarramendi
Juan M. Garcia-Illarramendi
CSChiara Sopegno
Chiara Sopegno
KFKaori L. Fonseca
Kaori L. Fonseca
LALilibeth Arias
Lilibeth Arias
KBKetevan Barbakadze
Ketevan Barbakadze
CVCris Vilaplana
Cris Vilaplana
Background: In extensively drug-resistant and pre–extensively drug-resistant TB, bacteriology-based monitoring often fails to capture structural lung recovery and patient-reported functional health. We aimed to characterize multidomain treatment response and examine host inflammatory and transcriptional features associated with incomplete recovery. Methods: We conducted an ancillary analysis of a prospective, open-label, pilot study evaluating adjunctive ibuprofen in XDR-TB ( NCT02781909 ). Participants were assessed at baseline and during treatment using TBS, chest radiography, sputum culture, SGRQ, blood cell indices, plasma cytokines, and whole-blood transcriptomic profiling. Clinical and laboratory measures were compared across outcome groups, and blood transcriptional profiles were analyzed in relation to treatment outcomes. Results: Here we show that microbiological and symptomatic improvement occurred earlier than radiological and functional recovery. Higher baseline systemic inflammation, including elevated NLR, SII, and IL-6, as well as increased expression of interferon-related genes such as CD274 and GBP5 , were associated with poorer radiological and SGRQ outcomes at 6 months. In contrast, transient elevations of IL-8 and IL-4 were associated with early bacteriological clearance. IL-8 was the only plasma biomarker consistently correlated with symptom severity, radiological findings, and functional health. Conclusions: Treatment response in drug-resistant TB is asynchronous across biological domains. Integrated host profiling identifies inflammatory and transcriptional features associated with incomplete structural and functional recovery, supporting the use of multidimensional endpoints to better capture long-term outcomes and inform individualized patient management. Plain Language Summary: People with highly drug-resistant tuberculosis can clear the infection but still experience lung damage and reduced quality of life after treatment. In this study, we examined recovery using several measures, including symptoms, chest X-rays, blood markers of inflammation, and gene activity, in addition to tests for tuberculosis bacteria. We analyzed data and stored samples from a small clinical trial to see how these measures changed over time. We found that lung structure and quality of life improved more slowly than bacterial clearance. People with higher levels of inflammation before treatment were more likely to have ongoing lung changes and poorer quality of life later. These results suggest that tuberculosis care should look beyond bacterial clearance and include monitoring inflammation to better support long-term recovery.

2 November 2026 in United European Gastroenterology Journal
Verified
Journal Article
Open access
ARAlice Rustichelli
Alice Rustichelli
JGJuan Manuel Garcia‐Illarramendi
Juan Manuel Garcia‐Illarramendi
JSJavier Santos
Javier Santos
AGAna Maria González
Ana Maria González
MSMagnus Simrén
Magnus Simrén
RFRicard Farre
Ricard Farre
Background: Irritable bowel syndrome (IBS) is a disorder of gut‐brain interaction often accompanied by psychiatric and/or somatic comorbidities. Intestinal‐barrier dysfunction has been implicated in IBS pathophysiology. However, the contribution of psychiatric and somatic comorbidities to intestinal permeability remains unclear. We aimed to assess intestinal permeability in a large multicentric cohort of IBS patients with and without psychiatric and/or somatic comorbidities, compared with disease controls, and healthy subjects. Methods: IBS patients and disease controls were recruited across nine European centres. Small intestinal and colonic permeabilities were assessed using the lactulose‐mannitol‐sucralose urinary excretion test. Urinary sugar concentrations were quantified by gas chromatography‐mass spectrometry. Analyses were adjusted for relevant clinical and lifestyle confounders. Results: The lactulose/mannitol (L/M) ratio, but not the percentage of sucralose (%S), was significantly increased in IBS patients ( N = 418) compared with disease controls ( N = 200), regardless of IBS subtype or sex. Notably, the increased L/M in IBS patients was primarly driven by a significant decrease in mannitol excretion. IBS patients with psychiatric or combined psychiatric and somatic comorbidities showed a higher L/M than their corresponding disease control groups. However, L/M values did not differ between IBS patients with and without comorbidities. Substantial between‐centre variability in L/M ratios awas observed. Discussion: Small intestinal, but not colonic, permeability, as reflected by an elevated L/M ratio, is increased in IBS patients. These alterations seem to be related to the presence of IBS per se rather than to comorbid conditions. Interestingly, substantial geographic variability was observed, which may reflect environmental or population‐related factors influencing barrier function. Further investigations are needed to better understand the clinical relevance of these findings.